Etanercept therapy for psoriasis in a patient with active pulmonary tuberculosis.
Anti-tumor necrosis factor alpha agents are effective treatments for psoriasis. However, the use of these agents is associated with an increased risk of tuberculosis reactivation. An algorithmic approach to screening for latent tuberculosis infection has been recommended to minimize the risk of tuberculosis reactivation. However, clinical suspicion should override the results of screening tests. This report describes the case of a 49-year-old man who experienced reactivation of latent tuberculosis during treatment with etanercept, despite a negative tuberculin skin test and chest radiograph showing no abnormalities before the commencement of etanercept therapy; this patient was able to receive further treatment with etanercept following treatment for tuberculosis.
Huo
Ran
R
Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1444 N.W. 9th Avenue, Room 309, Miami, FL, USA.
Romanelli
Paolo
P
D000995:Antitubercular Agents / Q000627:therapeutic use; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008403:Mass Screening / Q000379:methods; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D014374:Tuberculin Test; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000995:Antitubercular Agents; D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept